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Relationships of Basal Level of Serum 17-Hydroxyprogesterone 
with that of Serum Androstenedione and Their Stimulated 
Responses to a Low Dose of ACTH in Young Adult Patients with 
Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
A single measurement of serum 17α-hydroxyprogesterone (17OHP) level can be unreliable 
because of its marked diurnal variation. We investigated the relationship of serum level of 
17OHP with that of androstenedione (AD), which shows a smaller diurnal variation. And 
we tested whether the responses of these two hormones to low–dose ACTH stimulation are 
correlated in patients with 21-hydroxylase deficiency. Baseline serum 17OHP and AD levels 
were measured in 87 patients and a low-dose ACTH stimulation test was performed in 41 
patients. The basal 17OHP level correlated positively with the basal AD level independently 
of sex, type of 21-hydroxylase deficiency, and the time of day of blood sampling (n = 87, 
R
2 = 0.75, P < 0.001). The area under the curve of 17OHP and AD correlated positively 
with their respective basal levels. The fold–change increase in 17OHP after ACTH injection 
correlated negatively with the basal 17OHP level, but that of AD did not correlate with the 
basal AD level. The random serum 17OHP level, used in the clinic, is a reliable guide and a 
low-dose ACTH stimulation test provides no extra benefit for assessing the treatment 
adequacy in patients with 21-hydroxylase deficiency.
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INTRODUCTION
21-Hydroxylase deficiency is the most common cause of congen-
ital adrenal hyperplasia (CAH), which accounts for about 95% 
of all forms of CAH. The inability to convert 17α-hydroxyproges-
terone (17OHP) to 11-deoxycortisol causes cortisol deficiency 
and the accumulation of 17OHP. From 1940, 24 hr urine samples 
were analyzed to measure the levels of the 17-ketogenic steroids, 
such as 17-ketosteroid and 17-hydroxycorticosteroid, to diag-
nose this disorder and to monitor the adequacy of therapy (1). 
However, 24 hr urine samples was difficult to collect, and mea-
surement of these urinary hormones was often unreliable in 
those days (2). Measurement of serum 17OHP was introduced 
in 1968 (3), and it is now used most widely for the diagnosis and 
assessment of the adequacy of treatment (4). Measurement of 
serum androstenedione (AD) level was introduced at a similar 
time (5) and has been used to monitor the adequacy of treat-
ment in some studies since the late 1970s (2, 6, 7).
  A single determination of serum 17OHP level does not always 
reflect the adequacy of therapy in CAH patients because of its 
marked diurnal variation (8) and rapid changes in its concentra-
tion after a single dose of oral or intramuscular glucocorticoid 
(2). By contrast, serum AD level has a smaller diurnal variation 
than serum 17OHP and is not affected immediately by a single 
dose of oral or intramuscular glucocorticoid (2). Some studies 
have reported that serum AD level gives a more accurate param-
eter for assessing the adequacy of therapy for this disorder (2, 6, 
7). However, measurement of serum AD level is not available in 
practice because of the national medical insurance uncoverage 
in Korea. It is measured in a private laboratory or the blood sam-
ples are sent to foreign laboratories for testing. 
  Adrenal stimulation with adrenocorticotropic hormone (ACTH) is 
the principal challenge test used to estimate the relative activity 
of adrenocortical enzymes (9) and is used in the biochemical di-
agnosis of CAH (10). Low-dose (1 µg) ACTH stimulation test is 
accepted as the standard test of the pituitary-adrenal function and 
to investigate physiologic adrenal sensitivity (11). However, there 
are insufficient data about the response of adrenal steroidogene-
sis to low-dose ACTH stimulation in patients with CAH who take 
glucocorticoid medication. We hypothesized that the exaggerat-
ed serum 17OHP and AD responses to 1 µg ACTH might reflect 
poor control of the adrenal enzyme defect in CAH patients (12).
  We performed this study to observe the relationship between 
serum 17OHP and AD levels, and to investigate whether these Kang MJ, et al.  •  Serum 17OHP and Androstenedione in Patients with Congenital Adrenal Hyperplasia
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two hormonal responses to low-dose ACTH stimulation corre-
late with each other in patients with CAH caused by 21-hydrox-
ylase deficiency.
MATERIALS AND METHODS
Patients 
Eighty-seven patients (46 males and 41 females) being treated 
for CAH caused by 21-hydroxylase deficiency were included. 
The patients, who were not reached to their final adult height, 
were excluded. Of the 87 patients, 57 (65.5%) had the salt-wast-
ing (SW) type and 30 (34.5%) had the simple virilizing (SV) type. 
Their mean age at the time of the study was 19.1 ± 4.5 yr. No pa-
tient had clinical or biochemical evidence of hepatic or renal 
diseases, and none was taking medications except for glucocor-
ticoid and mineralocorticoid drugs. 
Methods
Patients visited the outpatient clinic for regular follow up, and 
standard anthropometric measurements were obtained. In gen-
eral, most patients with CAH achieve a final adult height (FAH) 
less than their target height (13). Therefore, the FAH, expressed 
as a standard deviation score (SDS), was corrected for genetic 
potential (FAH SDS minus midparental height SDS). We also 
reviewed the medical records to check the time of diagnosis, 
dose of medications at the time of blood sampling, and recent 
plasma renin activity (PRA) levels. Disease duration was calcu-
lated as time of diagnosis to the time of blood sampling.
  Between July 2010 and August 2010, blood was drawn in all 
patients at random times, regardless of the timing of the medi-
cations, for analysis of baseline serum 17OHP and AD concen-
trations. The low-dose ACTH stimulation test was performed in 
41 patients who agreed to participate with the test protocol. We 
arbitrarily divided the sampling time into two sessions, 0900-
1200 hr (morning) and 1200-1600 hr (afternoon), because se-
rum 17OHP concentration was expected to be high in the morn-
ing (14). Blood samples were collected from 31 patients in the 
morning and 56 patients in the afternoon.
ACTH test protocol
An indwelling catheter was inserted at least 10 min before sam-
pling to allow a period of adaptation. One microgram of tetraco-
sactide acetate (Synacthen
®, Ciba Geigy, Basle, Switzerland) was 
given intravenously to stimulate adrenal steroidogenesis and 
release. Blood was collected immediately before and after 1 hr 
the injection of Synacthen. The samples were centrifuged and 
separated, and the serum was stored at -20°C until the assays.
Assays
17OHP concentration was measured using the Coat-A-Count 
assay (Siemens Medical Solutions Diagnostics, Los Angeles, CA, 
USA). This is a solid-phase radioimmunoassay (RIA) with a sen-
sitivity of 0.07 ng/mL. The intraassay coefficient of variation (CV) 
was 7.1% at a serum concentration of 1.4 ng/mL, and the inter-
assay CV was 7.3% at a serum concentration of 1.5 ng/mL.
  AD concentration was measured using the Coat-A-Count as-
say (Siemens Medical Solutions Diagnostics). This is a solid-phase 
RIA with a sensitivity of 0.04 ng/mL. The intraassay CV was 5.0% 
at a serum concentration of 1.0 ng/mL, and the interassay CV 
was 7.0% at a serum concentration of 1.0 ng/mL.
Statistics
The biochemical data are presented as median and range (min-
imum, maximum) and the other continuous data are shown as 
mean ± SD. Statistical analyses were performed using SPSS 17.0 
for Windows (SPSS Inc., Chicago, IL, USA). The biochemical 
data, 17OHP and AD concentrations, and PRA levels, were trans-
formed to logarithmic values to make them parametric. The two 
groups were classified according to sex, type of CAH, and the time 
of blood sampling, and were then compared by Student’s t test 
and the chi-square test. Pearson’s correlation coefficient was 
used to identify correlations between biochemical variables. 
Fisher’s Z transformation was used to compare two correlation 
matrices. The response to ACTH stimulation was calculated two 
ways: 1) the fold-change increment, determined as the ratio of 
the peak level to basal value and 2) the overall response, deter-
mined by the area under the curve (AUC) for the response to 
ACTH of 17OHP and AD concentrations. Simple comparisons 
between the basal and peak biochemical values were analyzed 
using a paired t test. Because of the unbalanced distribution of 
the main serum predictors, we did not adjust for other variables 
(for example, by using a logistic regression model). P values       
< 0.050 were considered significant.
Ethics statement
The study protocol was approved by the institutional review 
board of Seoul National University Hospital (H-1002-066-310). 
Written informed consent was obtained from patients and their 
parents at the beginning of the study.
RESULTS
Clinical characteristics of the patients
At the time of blood sampling, the mean age was greater in the 
patients with the SV type than in those with the SW type, but the 
disease duration did not differ significantly according to type of 
disease. Except for the sex ratio, the corrected FAH SDS, body 
mass index (BMI) SDS, and dose of medications did not differ 
between the SV and SW patients (Table 1). However, the mean 
corrected FAH SDS was lower in males than in females (male, 
-1.72 ± 1.27 vs female, -0.93 ± 1.05; P = 0.002). BMI SDS did not 
differ between males and females (Table 2).Kang MJ, et al.  •  Serum 17OHP and Androstenedione in Patients with Congenital Adrenal Hyperplasia
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Basal serum 17OHP and AD concentrations
The median basal concentrations of serum 17OHP, AD, and PRA 
in the 87 patients were 28.00 (0.10, 608.00) ng/mL, 3.18 (0.15, 
36.85) ng/mL, and 11.1 (0.1, 86.0) ng/mL/h, respectively. These 
values did not differ significantly between males and females 
(Table 2), between SV and SW patients, or between different 
blood sampling times.
  The basal 17OHP concentration correlated positively with the 
basal AD concentration (n = 87, R
2 = 0.75, P < 0.001). The cor-
relation coefficient was bigger in the morning samples (n = 31, 
R
2 = 0.81, P < 0.001) than in the afternoon samples (n = 56, R
2 =  
0.70, P < 0.001), although this difference was not significant (Fig. 
1). The correlation between basal serum levels of 17OHP and 
AD was not related to sex or type of CAH.
Low-dose ACTH stimulation test
The median peak serum 17OHP concentration was 77.80 (1.46, 
486.00) ng/mL and the peak serum AD concentration was 4.20 
(0.72, 40.75) ng/mL in 41 patients. Both peak levels were signifi-
cantly higher than their basal levels (17OHP, P < 0.001; AD, P =  
0.015) (Fig. 2) and for each markers, the basal and peak levels 
correlated significantly (17OHP, R
2 = 0.82, P < 0.001; AD, R
2 =  
0.89, P < 0.001). The AUC of 17OHP and AD correlated positive-
ly with their respective basal levels (17OHP, R
2 = 0.93, P < 0.001; 
AD, R
2 = 0.97, P < 0.001) (Fig. 3A, B). The peak levels and AUC 
of these biochemical markers did not differ between males and 
females, according to the type of CAH, or between blood sam-
pling times (Table 3).
  The fold-change increment in 17OHP concentration after the 
low-dose ACTH injection correlated negatively with the basal 
17OHP concentration (R
2 = 0.50, P < 0.001) but did not differ 
between males and females, between type of CAH, or between 
blood sample times. The median increment in AD concentra-
tion was 1.13-fold, and this value did not correlate significantly 
with the basal AD concentration (Fig. 3C, D).
DISCUSSION
The recent clinical guidelines suggest the target levels of multi-
ple adrenal hormones, such as 17OHP and AD, and recommend 
glucocorticoid dose titration according to the target levels (15-
17). In our study, the basal serum 17OHP concentration corre-
lated well with that of serum AD irrespective of sex, CAH type, 
and the time of blood sampling. This result suggests that mea-
suring serum AD concentration gives no additional informa-
tion for assessing the treatment in these patients. 
  Cavallo et al. (2) reported that serum AD level correlates well 
with urinary 17-ketosteroid level and with clinical control in CAH 
patients. In their study, serum AD level was normal in most pa-
tients with good control, regardless of the time of the day when 
the blood sample was obtained, but it was elevated in all pati-
ents with poor control. Conway et al. (12) showed that the serum 
AD response was normal in adequately treated patients. Ilondo 
et al. (18) reported that serum 17OHP level varies widely irrespec-
tive of the degree of control and can be abnormally high even in 
patients with good clinical and biochemical control. All of these 
researchers suggested that the serum AD level is better than the 
Table 1. Clinical characteristics of the patients
Parameters Total (n = 87) Salt-wasting type (n = 57) Simple virilizing type (n = 30) P value
Male:female 46:41 35:22 11:19 0.028*
Age at the time of blood sampling (yr) 19.1 ± 4.5 18.1 ± 3.8 21.1 ± 5.2 0.008
Disease duration (yr) 17.3 ± 4.7 17.8 ± 3.8 16.4 ± 5.9 0.267
Corrected FAH SDS  -1.35 ± 1.23  -1.48 ± 1.24  -1.11 ± 1.21 0.184
BMI SDS   0.76 ± 1.09   0.78 ± 1.10   0.72 ± 1.08 0.814
HCS:PD 10:77 7:50 3:27 1.000*
HCS-equivalent dose (mg/m
2/day) 17.9 ± 2.4 17.7 ± 2.3 18.2 ± 2.6 0.343
Fludrocortisone dose (mg/day) 0.12 ± 0.03 (n = 72) 0.12 ± 0.03 (n = 56) 0.12 ± 0.03 (n = 16) 0.660
Data are expressed as mean ± standard deviation. *by chi-square test. FAH, final adult height; SDS, standard deviation score; BMI, body mass index; HCS, hydrocortisone; PD, 
prednisolone.
Table 2. Comparison of clinical characteristics and basal levels of serum 17OHP and 
AD between males and females
Parameters Male (n = 46) Female (n = 41) P value
SW:SV 35:11 22:19 0.028* 
Age at the time of blood sampling (yr) 18.7 ± 4.0 19.6 ± 5.0 0.325
Disease duration (yr) 17.0 ± 4.8 17.7 ± 4.5 0.447
Corrected FAH SDS  -1.72 ± 1.27  -0.93 ± 1.05 0.002
BMI SDS   0.71 ± 1.14   0.83 ± 1.03 0.608
HCS:PD 7:39 3:38 0.323
HCS-equivalent dose (mg/m
2/day) 17.2 ± 2.0 18.6 ± 2.6 0.006
Fludrocortisone dose (mg/day)   0.13 ± 0.04 
(n = 42)
  0.11 ± 0.02 
(n = 30)
0.036
Sample time (morning:afternoon) 17:29 14:27 0.826*
Basal 17OHP (ng/mL) 39.65  
(1.00, 427.00)
23.00  
(0.10, 608.00)
0.082
Basal AD (ng/mL) 3.41  
(0.60, 24.66)
2.45  
(0.15, 36.85)
0.503
PRA (ng/mL/h) 10.8  
(0.5, 62.4)
11.4  
(0.1, 86.0)
0.422
Data are expressed as mean ± standard deviation or median (range). *by chi-square 
test. SW, salt-wasting CAH; SV, simple virilizing CAH; FAH, final adult height; SDS, stan-
dard deviation score; BMI, body mass index; HCS, hydrocortisone; PD, prednisolone; 
17OHP, 17α-hydroxyprogesterone; AD, androstenedione, PRA, plasma renin activity. 
Conversion factors: 17OHP, ng/mL × 3.02 → nM/L; AD, ng/mL × 3.49 → nM/L.Kang MJ, et al.  •  Serum 17OHP and Androstenedione in Patients with Congenital Adrenal Hyperplasia
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serum 17OHP level for monitoring therapy in patients with CAH. 
However, a single serum determination of androgen level may 
not reflect total daily androgen secretion because of the known 
episodic and diurnal variation of secretion (19). Some recom-
mend that three or four determinations are needed throughout 
the day to provide a reliable indicator of the control of treatment 
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Fig. 2. The basal and peak hormone levels after the low–dose ACTH stimulation test. (A) 17OHP. (B) AD. Both peak levels were significantly higher than their respective basal 
levels (17OHP, P < 0.001; AD, P = 0.015). Conversion factors: 17OHP, ng/mL × 3.02 → nM/L; AD, ng/mL × 3.49 → nM/L.
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Fig. 1. The relationship between basal levels of serum 17OHP and AD. The basal hor-
mone levels were correlated positively with each other in all patients (A). The correla-
tion coefficient was higher in the morning samples (B) than in afternoon samples (C). 
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Fig. 3. Simple correlations of the basal hormone levels with their responses to ACTH stimulation. (A, B) Overall responses. (C, D) The fold-change increments. Conversion factors: 
17OHP, ng/mL × 3.02 → nM/L; AD, ng/mL × 3.49 → nM/L.
(20). By contrast, one study that used continuous 24 hr sampling 
suggested that serum AD level exhibits relatively small fluctua-
tions and that random samples are likely to be representative (7). 
The question whether a single measurement of serum AD level 
is adequate remains controversial. Because we did not apply a 
clinical standard of disease control in our study, we could not 
directly compare the accuracy of serum 17OHP and AD levels. 
However, our data suggest that information about the disease 
control status based on the serum 17OHP level is the same as 
that based on both serum 17OHP and AD levels.
Table 3. Serum 17OHP and AD responses to the low-dose ACTH stimulation test in 41 patients
Parameters Total (n = 41) Male (n = 20) Female (n = 21) P value
Blood sample time (morning:afternoon) 21:20 13:7 8:13 0.121*
Basal 17OHP (ng/mL) 36.20 (0.47, 608.00) 30.85 (4.39, 427.00) 43.90 (0.47, 608.00) 0.844
Peak 17OHP (ng/mL) 77.80 (1.46, 486.00) 68.85 (11.08, 397.00) 77.80 (1.46, 486.00) 0.547
Basal AD (ng/mL) 3.12 (0.48, 36.85) 2.61 (0.68, 14.00) 3.83 (0.48, 36.85) 0.536
Peak AD (ng/mL) 4.20 (0.72, 40.75) 3.50 (0.99, 23.70) 5.01 (0.72, 40.75) 0.828
AUC 17OHP (ng/mL × 60 min) 3333.00 (57.90, 29340.00) 3102.00 (464.10, 24720.00) 3333.00 (57.9, 29340.00) 0.694
AUC AD (ng/mL × 60 min) 221.40 (37.35, 2328.00) 176.85 (50.10, 1101.00) 257.10 (37.35, 2328.00) 0.681
Peak/basal ratio 17OHP 1.91 (0.40, 9.79) 2.28 (0.58, 6.45) 1.57 (0.40, 9.79) 0.564
Peak/basal ratio AD 1.13 (0.48, 2.51) 1.34 (0.67, 2.51) 1.03 (0.48, 2.11) 0.212
Data are expressed as median (range). *by chi-square test. 17OHP, 17α-hydroxyprogesterone; AD, androstenedione; AUC, area under the curve. Conversion factors: 17OHP, 
ng/mL × 3.02 → nM/L; AD, ng/mL × 3.49 → nM/L.Kang MJ, et al.  •  Serum 17OHP and Androstenedione in Patients with Congenital Adrenal Hyperplasia
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  The correlation between basal 17OHP and AD concentrations 
tended to be strongest in the morning. This observation is simi-
lar to that reported by Charmandari et al. (14), who also found 
that the morning sample, taken before the oral dose of hydro-
cortisone, is most accurate for assessing disease control status. 
In our study, we could not accurately predict the degree of sup-
pression of the pituitary-adrenal axis by glucocorticoids because 
of variable sampling times. Further investigation of the gluco-
corticoid effect should be needed.
  We expected that patients with poor control would have a 
high basal level and an exaggerated peak response of 17OHP 
after low-dose ACTH administration and vice versa. In contrast 
to our expectation, the fold-change increment in serum 17OHP 
level after ACTH administration correlated negatively with the 
basal level, suggesting that ACTH stimulation test provides no 
additional information for assessing the adequacy of treatment. 
The patients with low serum 17OHP level had a greater fold-
change increment in serum 17OHP level. However, we could 
not interpret this clinical meaning because of the absence of 
normal data for the control group. The fold-change increment 
was smaller for serum AD level than for serum 17OHP level, al-
though the peak AD level was significantly higher than the bas-
al AD level. These data suggest that the low-dose ACTH stimu-
lation test was not effective in assessing the degree of disease 
control in CAH patients in our study.
  A limitation of our study was the absence of a gold standard 
to assess disease control in our patients. In prepubertal and pu-
bertal patients, growth velocity and bone age advancement are 
key components for determining the degree of clinical control. 
However, there are no clinical criteria that can be used for post-
pubertal patients in the outpatient clinic. Some have used 24 hr 
urinary 17-ketosteroid excretion (6, 7) but this test cannot be per-
formed practically. And because the insufficiency of glucocorti-
coid and/or mineralocorticoid therapy may take several months 
to appear as virilization and hyperpigmentation, serum 17OHP 
and/or AD levels may increase before these clinical signs be-
come obvious. Another limitation of our study was the absence 
of data from the ACTH stimulation test in a normal control group 
to compare with the results in the patients.
  In conclusion, serum 17OHP concentration correlates well 
with serum AD concentration independently of sex, type of CAH, 
and the time of day of blood sampling. The low-dose ACTH stim-
ulation test does not provide additional information for assess-
ing the treatment adequacy in patients with CAH. Therefore the 
random serum 17OHP level, as currently measured in the clinic, 
appears to be a reliable guide for the management of patients 
with CAH.
ACKNOWLEDGMENTS
We acknowledge the assistance of Tae Hun Kim, a senior tech-
nologist at the Department of Nuclear Medicine at Seoul National 
University Hospital, in the measurements of serum 17-hydroxy-
progesterone and androstenedione levels.
REFERENCES
1. Gardner R, Snaith AH. The urinary excretion of 17-hydroxysteroids in 
children. Arch Dis Child 1958; 33: 305-6.
2. Cavallo A, Corn C, Bryan GT, Meyer WJ III. The use of plasma androstene-
dione in monitoring therapy of patients with congenital adrenal hyper-
plasia. J Pediatr 1979; 95: 33-7.
3. Strott CA, Lipsett MB. Measurement of 17-hydroxyprogesterone in hu-
man plasma. J Clin Endocrinol Metab 1968; 28: 1426-30.
4. Barnes ND, Atherden SM. Diagnosis of congenital adrenal hyperplasia 
by measurement of plasma 17-hydroxyprogesterone. Arch Dis Child 1972; 
47: 62-5.
5. Horton R, Frasier SD. Androstenedione and its conversion to plasma tes-
tosterone in congenital adrenal hyperplasia. J Clin Invest 1967; 46: 1003-9.
6. Korth-Schutz S, Virdis R, Saenger P, Chow DM, Levine LS, New MI. Se-
rum androgens as a continuing index of adequacy of treatment of con-
genital adrenal hyperplasia. J Clin Endocrinol Metab 1978; 46: 452-8.
7. Keenan BS, McNeel R, Barrett GN, Holcombe JH, Kirkland RT, Clayton 
GW. Plasma androgens in congenital adrenal hyperplasia: androstene-
dione concentration as an index of adrenal androgen suppression. J Lab 
Clin Med 1979; 94: 799-808.
8. Strott CA, Yoshimi T, Lipsett MB. Plasma progesterone and 17-hydroxy-
progesterone in normal men and children with congenital adrenal hy-
perplasia. J Clin Invest 1969; 48: 930-9.
9. Colak R, Keleştimur F, Unlühizarci K, Bayram F, Sahin Y, Tutuş A. A com-
parison between the effects of low dose (1 microg) and standard dose (250 
microg) ACTH stimulation tests on adrenal P450c17alpha enzyme ac-
tivity in women with polycystic ovary syndrome. Eur J Endocrinol 2002; 
147: 473-7.
10. Unlühizarci K, Keleştimur F, Güven M, Bayram F, Colak R. The value of 
low dose (1 microg) ACTH stimulation test in the investigation of non-
classic adrenal hyperplasia due to 11beta-hydroxylase deficiency. Exp 
Clin Endocrinol Diabetes 2002; 110: 381-5.
11. Luboshitzky R, Ishai A, Shen-Or Z, Herer P. Evaluation of the pituitary-
adrenal axis in hyperandrogenic women with polycystic ovary syndrome. 
Neuro Endocrinol Lett 2003; 24: 249-54.
12. Conway DI, Anderson DC, Bu’lock DE. The steroid response to controlled 
adrenal stimulation in congenital adrenal hyperplasia. Clin Endocrinol 
(Oxf) 1982; 16: 215-26.
13. Yi KH. Effect on final height of gonadotropin-releasing hormone agonist 
(GnRHa) in children with congenital adrenal hyperplasia. J Korean Soc 
Pediatr Endocrinol 2005; 10: 50-6. 
14. Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. 
Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hy-
droxylase deficiency: is current replacement therapy satisfactory? J Clin 
Endocrinol Metab 2001; 86: 4679-85.
15. Hindmarsh PC. Management of the child with congenital adrenal hy-
perplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 193-208.
16. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 
2003; 349: 776-88.
17. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Mey-Kang MJ, et al.  •  Serum 17OHP and Androstenedione in Patients with Congenital Adrenal Hyperplasia
1460   http://jkms.org http://dx.doi.org/10.3346/jkms.2011.26.11.1454
er-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White 
PC; Endocrine Society. Congenital adrenal hyperplasia due to steroid 
21-hydroxylase deficiency: an Endocrine Society clinical practice guide-
line. J Clin Endocrinol Metab 2010; 95: 4133-60.
18. Ilondo MM, Vanderschueren-Lodeweyckx M, Pizarro M, Vlietinck R, 
Malvaux P, Eggermont E, Eeckels R. Plasma levels of androgens and 17 
alpha-OH-progesterone as an index of the adequacy of treatment in con-
genital adrenal hyperplasia. Horm Res 1983; 18: 175-85.
19. Ghizzoni L, Bernasconi S, Virdis R, Vottero A, Ziveri M, Volta C, Iughetti 
L, Giovannelli G.  Dynamics of 24-hour pulsatile cortisol, 17-hydroxypro-
gesterone, and androstenedione release in prepubertal patients with non-
classic 21-hydroxylase deficiency and normal prepubertal children. Me-
tabolism 1994; 43: 372-7.
20. von Schnakenburg K, Bidlingmaier F, Knorr D. 17-hydroxyprogesterone, 
androstenedione, and testosterone in normal children and in prepuber-
tal patients with congenital adrenal hyperplasia. Eur J Pediatr 1980; 133: 
259-67.
AUTHOR SUMMARY
Relationships of Basal Level of Serum 17-Hydroxyprogesterone with that of Serum 
Androstenedione and Their Stimulated Responses to a Low Dose of ACTH in Young 
Adult Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Min Jae Kang, Shin Mi Kim, Young Ah Lee, Choong Ho Shin and Sei Won Yang
Because a single measurement of serum 17α-hydroxyprogesterone (17OHP) level can be unreliable due to its diurnal variation, we 
investigated the relationship between serum level of 17OHP and androstenedione (AD). Our results indicate that the basal 17OHP 
level correlated positively with the basal AD level that has smaller diurnal variation. However, the foldchange increase of both 
hormones after ACTH injection showed no consistent result. The random serum 17OHP level may be a reliable guide and a lowdose 
ACTH stimulation test provides no extra benefit for assessing the treatment adequacy in patients with 21-hydroxylase deficiency.